WallStreetZenWallStreetZen

NASDAQ: IPSC
Century Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IPSC

Based on 1 analyst offering 12 month price targets for Century Therapeutics Inc

Min Forecast
$2.00-7.83%
Avg Forecast
$2.00-7.83%
Max Forecast
$2.00-7.83%

Should I buy or sell IPSC stock?

Based on 1 analyst offering ratings for Century Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IPSC's forecast from analysts indicates a "Hold", our proven Zen Rating quant model rates IPSC as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their IPSC stock forecasts and price targets.

IPSC stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-17

1 of 1

Forecast return on equity

Is IPSC forecast to generate an efficient return?

Company
N/A
Industry
355.6%
Market
208.52%

Forecast return on assets

Is IPSC forecast to generate an efficient return on assets?

Company
N/A
Industry
123.2%

IPSC earnings per share forecast

What is IPSC's earnings per share in the next 2 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.70
Avg 2 year Forecast
-$0.58

IPSC revenue forecast

What is IPSC's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0-100%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
IPSC's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

IPSC revenue growth forecast

How is IPSC forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
114.46%
Market
23.4%
IPSC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
IPSC's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

IPSC vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IPSC$2.17$2.00-7.83%Hold
SABS$3.98$10.75+170.10%Strong Buy
CBIO$13.51$25.50+88.75%Strong Buy
TLSA$1.68N/AN/A
RNAC$7.42$38.67+421.12%Strong Buy
View Top Biotech Stocks

Century Therapeutics Stock Forecast FAQ

Is Century Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: IPSC) stock is to Hold IPSC stock.

Out of 1 analyst, 0 (0%) are recommending IPSC as a Strong Buy, 0 (0%) are recommending IPSC as a Buy, 1 (100%) are recommending IPSC as a Hold, 0 (0%) are recommending IPSC as a Sell, and 0 (0%) are recommending IPSC as a Strong Sell.

If you're new to stock investing, here's how to buy Century Therapeutics stock.

What is IPSC's earnings growth forecast for 2026-2027?

(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 70.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.85%.

Century Therapeutics's earnings in 2026 is -$26,476,000.On average, 6 Wall Street analysts forecast IPSC's earnings for 2026 to be -$61,446,731, with the lowest IPSC earnings forecast at -$77,004,854, and the highest IPSC earnings forecast at -$32,085,356.

In 2027, IPSC is forecast to generate -$50,315,077 in earnings, with the lowest earnings forecast at -$66,737,540 and the highest earnings forecast at -$32,085,356.

What is IPSC's revenue growth forecast for 2026-2028?

(NASDAQ: IPSC) Century Therapeutics's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 114.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.4%.

Century Therapeutics's revenue in 2026 is $113,337,000.On average, 6 Wall Street analysts forecast IPSC's revenue for 2026 to be $0, with the lowest IPSC revenue forecast at $0, and the highest IPSC revenue forecast at $0. On average, 4 Wall Street analysts forecast IPSC's revenue for 2027 to be $0, with the lowest IPSC revenue forecast at $0, and the highest IPSC revenue forecast at $0.

In 2028, IPSC is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is IPSC's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IPSC) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 123.2%.

What is IPSC's Price Target?

According to 1 Wall Street analyst that have issued a 1 year IPSC price target, the average IPSC price target is $2.00, with the highest IPSC stock price forecast at $2.00 and the lowest IPSC stock price forecast at $2.00.

The Wall Street analyst predicted that Century Therapeutics's share price could fall to $2.00 by Nov 17, 2026. The average Century Therapeutics stock price prediction forecasts a potential downside of 7.83% from the current IPSC share price of $2.17.

What is IPSC's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: IPSC) Century Therapeutics's current Earnings Per Share (EPS) is -$0.32. On average, analysts forecast that IPSC's EPS will be -$0.70 for 2026, with the lowest EPS forecast at -$0.88, and the highest EPS forecast at -$0.37. In 2027, IPSC's EPS is forecast to hit -$0.58 (min: -$0.76, max: -$0.37).

What is IPSC's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IPSC) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.